BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24373724)

  • 1. Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating of chronic kidney diseases.
    Kato Y; Fuchi N; Nishimura Y; Watanabe A; Yagi M; Nakadera Y; Higashi E; Yamada M; Aoki T; Kigoshi H
    Bioorg Med Chem Lett; 2014 Jan; 24(2):565-70. PubMed ID: 24373724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension.
    Kato Y; Fuchi N; Saburi H; Nishimura Y; Watanabe A; Yagi M; Nakadera Y; Higashi E; Yamada M; Aoki T
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5975-9. PubMed ID: 24035338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.
    Shen HC; Ding FX; Wang S; Xu S; Chen HS; Tong X; Tong V; Mitra K; Kumar S; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Chen X; Zhang B; Tata JR; Berger JP; Colletti SL
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3398-404. PubMed ID: 19481932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.
    Shen HC; Ding FX; Deng Q; Xu S; Chen HS; Tong X; Tong V; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Zhang B; Roy S; Tata JR; Berger JP; Colletti SL
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5314-20. PubMed ID: 19682899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action.
    Takai K; Nakajima T; Takanashi Y; Sone T; Nariai T; Chiyo N; Nakatani S; Ishikawa C; Yamaguchi N; Fujita K; Yamada K
    Bioorg Med Chem; 2014 Mar; 22(5):1548-57. PubMed ID: 24530032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors.
    Takai K; Chiyo N; Nakajima T; Nariai T; Ishikawa C; Nakatani S; Ikeno A; Yamamoto S; Sone T
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1705-1708. PubMed ID: 25800114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.
    Shen HC; Ding FX; Wang S; Deng Q; Zhang X; Chen Y; Zhou G; Xu S; Chen HS; Tong X; Tong V; Mitra K; Kumar S; Tsai C; Stevenson AS; Pai LY; Alonso-Galicia M; Chen X; Soisson SM; Roy S; Zhang B; Tata JR; Berger JP; Colletti SL
    J Med Chem; 2009 Aug; 52(16):5009-12. PubMed ID: 19645482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.
    Eldrup AB; Soleymanzadeh F; Farrow NA; Kukulka A; De Lombaert S
    Bioorg Med Chem Lett; 2010 Jan; 20(2):571-5. PubMed ID: 19969453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of polar spirocyclic orally bioavailable urea inhibitors of soluble epoxide hydrolase.
    Lukin A; Kramer J; Hartmann M; Weizel L; Hernandez-Olmos V; Falahati K; Burghardt I; Kalinchenkova N; Bagnyukova D; Zhurilo N; Rautio J; Forsberg M; Ihalainen J; Auriola S; Leppänen J; Konstantinov I; Pogoryelov D; Proschak E; Dar'in D; Krasavin M
    Bioorg Chem; 2018 Oct; 80():655-667. PubMed ID: 30059891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent non-urea inhibitors of soluble epoxide hydrolase.
    Xie Y; Liu Y; Gong G; Smith DH; Yan F; Rinderspacher A; Feng Y; Zhu Z; Li X; Deng SX; Branden L; Vidović D; Chung C; Schürer S; Morisseau C; Hammock BD; Landry DW
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2354-9. PubMed ID: 19303288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptidyl-urea based inhibitors of soluble epoxide hydrolases.
    Morisseau C; Newman JW; Tsai HJ; Baecker PA; Hammock BD
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5439-44. PubMed ID: 16908134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.
    Kowalski JA; Swinamer AD; Muegge I; Eldrup AB; Kukulka A; Cywin CL; De Lombaert S
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3703-7. PubMed ID: 20472432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.
    Burmistrov V; Morisseau C; Danilov D; Harris TR; Dalinger I; Vatsadze I; Shkineva T; Butov GM; Hammock BD
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5514-9. PubMed ID: 26520661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
    Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
    J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of enantioselectivity of urea inhibitors of soluble epoxide hydrolase.
    Manickam M; Pillaiyar T; Boggu P; Venkateswararao E; Jalani HB; Kim ND; Lee SK; Jeon JS; Kim SK; Jung SH
    Eur J Med Chem; 2016 Jul; 117():113-24. PubMed ID: 27092411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility.
    Kim IH; Morisseau C; Watanabe T; Hammock BD
    J Med Chem; 2004 Apr; 47(8):2110-22. PubMed ID: 15056008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.
    Tsai HJ; Hwang SH; Morisseau C; Yang J; Jones PD; Kasagami T; Kim IH; Hammock BD
    Eur J Pharm Sci; 2010 Jun; 40(3):222-38. PubMed ID: 20359531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.
    Ghosh S; Chiang PC; Wahlstrom JL; Fujiwara H; Selbo JG; Roberds SL
    Basic Clin Pharmacol Toxicol; 2008 May; 102(5):453-8. PubMed ID: 18312493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
    Jones PD; Tsai HJ; Do ZN; Morisseau C; Hammock BD
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5212-6. PubMed ID: 16870439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N'-diaryl urea inhibitors of soluble epoxide hydrolase.
    Anandan SK; Gless RD
    Bioorg Med Chem Lett; 2010 May; 20(9):2740-4. PubMed ID: 20363133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.